‘Immediately Practice-Changing’ Trial in Small Cell Lung Cancer

By News Health
2 months Ago

(MedPage Today) — CHICAGO — The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment of small cell lung cancer (SCLC), a practice-changing phase III trial showed.
In patients whose…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115891

Author :

Publish date : 2025-06-03 21:16:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Vaccine Expert: My Grandchild Has Autism, but Vaccines Aren't to Blame

Vaping Declined in States With Flavor Bans -- But It's Not All Good News

Hospital Refuses to Disable Death Row Inmate's ICD; Dentist Gets Life Sentence

Ousted Vaccine Panel Members Say Rigorous Science Is Being Abandoned

Trump Overrules RFK Jr.; Giant Earthquake During Cancer Surgery; Ground Beef Recall

Critics of de-extinction research hit by mystery smear campaign